Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza
The Central Social Insurance Medical Council, better known as Chuikyo, approved on December 13 insurance coverage for the use of Chugai Pharmaceutical’s comprehensive genomic profiling test FoundationOne CDx Cancer Genome Profile as a companion diagnostic for the PARP inhibitor Lynparza…
To read the full story
Related Article
- Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
October 21, 2019
- Chugai’s Comprehensive Genomic Profiling Test Approved for Companion Diagnostic for Lynparza
September 26, 2019
- Japan OKs Companion Diagnostic for Rozlytrek: Chugai
June 28, 2019
- Chugai’s Gene Mutation Analysis Program Now Available in Japan
June 4, 2019
- Japan Approves Health Coverage for Cancer Gene Panel Tests
May 30, 2019
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Chugai Obtains Approval of First Dual-Function Gene Panel Test
December 28, 2018
REGULATORY
- PMDA Flags Severe Gastritis, Esophagitis with Checkpoint Inhibitors
August 26, 2026
- Japan Grants Sakigake Tag to NS-035, MSA-01
August 26, 2026
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…